Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a leading clinical-stage biopharmaceutical company headquartered in the United States, dedicated to the discovery and development of engineered monoclonal antibody and protein therapeutics. The primary goal of Xencor is to address severe and life-threatening diseases that currently have unmet medical needs, such as autoimmune diseases, asthma, and various forms of cancer.
Xencor leverages its proprietary XmAb® technology platform to enhance the natural immune functions of antibodies while maintaining a high degree of similarity to natural antibodies (over 99.5% identity). This innovative approach allows Xencor to create biotherapeutics that are more potent, safer, and longer-lasting, thereby improving patient outcomes and quality of life.
One of the key strengths of Xencor's XmAb technology is its ability to dramatically augment the immune functions of antibodies. This has resulted in a robust pipeline of product candidates, including eight in human clinical trials. Notable candidates in clinical development include XmAb5871 and XmAb7195, with several others such as XmAb14045 and XmAb662 in the pre-clinical stage. These candidates are being developed both by Xencor and in collaboration with pharmaceutical partners.
Financially, Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates. This collaborative approach not only advances their pipeline but also brings in essential funding to support ongoing and future projects.
Recently, Xencor has made significant strides in expanding its partnerships and advancing its clinical trials. These developments are crucial as they bring the company closer to delivering breakthrough treatments that can transform patient care in various therapeutic areas.
Overall, Xencor, Inc. stands out in the biopharmaceutical industry for its innovative approach to antibody and protein engineering, with a mission to fundamentally improve the treatment of serious diseases and enhance the quality of life for patients around the world.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced it will provide a corporate update and report financial results for Q4 and full year 2021 after market close on February 23, 2022. Management will host a conference call at 4:30 p.m. ET to discuss the updates. Xencor is developing engineered monoclonal antibodies and cytokines to treat cancer and autoimmune diseases, with 22 candidates currently in clinical development.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, will participate in two virtual investor conferences. The first is the Guggenheim Healthcare Talks | 2022 Oncology Conference on February 9, 2022, at 2:00 p.m. EST. The second is the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 p.m. EST. Live webcasts will be accessible on Xencor's website, with replays available for 30 days.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced its corporate priorities for 2022, focusing on advancing bispecific antibody and engineered cytokine programs for cancer and autoimmune diseases. Key projects include vudalimab and plamotamab, with planned Phase 2 studies in various cancers. Xencor reported a cash position of approximately $660 million, sufficient to fund operations through 2025. The company anticipates new clinical data that may enhance its portfolio, which includes 22 candidates in development, leveraging its XmAb technology.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference.
The recording will be accessible starting January 10, 2022, at 4:00 a.m. PT under the 'Events & Presentations' section on the company’s website for a duration of at least 30 days.
Xencor currently has 22 candidates in clinical development utilizing its XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) announced updated data from its Phase 1 study of plamotamab, a bispecific antibody targeting B-cell non-Hodgkin lymphoma. Results will be presented at the ASH Annual Meeting. The drug showed encouraging clinical activity, with a recommended Phase 2 dose established at 50 mg every two weeks. The study demonstrated a 51% objective response rate, with 100% in patients with follicular lymphoma. A collaboration with Janssen aims to advance plamotamab development. The treatment was generally well tolerated, with manageable adverse events.
Xencor has granted Zenas BioPharma exclusive rights to develop and commercialize the investigational antibody obexelimab, aimed at treating autoimmune diseases. This agreement includes an upfront payment in the form of additional equity, with Xencor eligible for up to
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced participation in two investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference is scheduled for
Xencor, Inc. (NASDAQ:XNCR) presented new data on its preclinical XmAb bispecific antibody programs and IL-12-Fc cytokine at the 36th Annual Meeting of the Society for Immunotherapy of Cancer. Highlights include the presentation of XmAb NK cell engagers and engineered IL-12 fusions showing strong anti-tumor activity with improved safety profiles. The company aims to submit an IND application for XmAb662 in 2022. These advancements underline Xencor’s innovative approach to drug development in oncology.
Xencor, Inc. (NASDAQ:XNCR) announced positive results from its Phase 1 trial of vudalimab, a PD-1 x CTLA-4 bispecific antibody, aimed at treating advanced solid tumors. The study, presented at the SITC meeting, showed vudalimab was generally well-tolerated with an objective response rate of 14.1%. Partial responses were noted in various cancers, including two in castration-resistant prostate cancer (CRPC). A complete response occurred in a patient with BRCA1+ ovarian cancer. Xencor plans to initiate Phase 2 studies for metastatic CRPC and advanced pelvic tumors.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, reported its third-quarter financials for 2021, revealing total revenue of $19.7 million, down from $35.4 million in 2020. The net loss widened to $40.2 million or $(0.69) per share, compared to a loss of $12.6 million or $(0.22) per share last year. Key developments include positive initial data from the Phase 1 study of XmAb306 and plans for upcoming presentations at major conferences. Looking ahead, Xencor expects to end 2021 with $575-$625 million in cash, supporting operations into 2025.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
What is Xencor, Inc.?
What is the XmAb technology?
What are some key products in Xencor's pipeline?
How does Xencor generate revenue?
Where is Xencor, Inc. based?
What diseases does Xencor target?
What makes Xencor's biotherapeutics unique?
Who are Xencor's partners?
What recent achievements has Xencor made?
What is the primary goal of Xencor?
